Cardinal Health Inc. operates with a distinctive pharmaceutical distribution model that generates substantial volume at compressed margins, evidenced by its gross margin of 3.76% and net margin of 0.62%. The company's $53.9 billion market capitalization reflects its position as a critical healthcare supply chain intermediary, though systematic screening highlights valuation tensions with a P/E (TTM) of 34.43 trading well above historical sector norms for low-margin distributors.

The fundamental profile reveals notable strengths in capital efficiency metrics. ROE of 37.17% stands materially elevated relative to the asset-light distribution model, amplified by a debt-to-equity ratio of 3.48 that magnifies returns through financial leverage. Revenue growth of 12.88% year-over-year indicates robust volume expansion, likely capturing pandemic-related demand shifts and generic drug launches. The beta of 0.53 positions the equity as a defensive healthcare infrastructure play with reduced volatility characteristics compared to broader market indices.

Material risk factors emerge from liquidity and leverage positioning:

• Current ratio of 0.94 falls below the 1.0 threshold, flagging potential working capital constraints in a business requiring extensive inventory management
• High financial leverage at 3.48x debt-to-equity amplifies sensitivity to interest rate fluctuations and operating disruptions
• Modest EPS growth of 2.26% trails revenue expansion significantly, suggesting margin compression or elevated costs

Research perspective versus peers MCK and COR: Cardinal Health's P/S of 0.21 trades at a narrower discount to revenue than typical distribution multiples warrant, while the 34.43x earnings multiple appears stretched. The screener flags McKesson as offering potentially superior valuation efficiency within pharmaceutical wholesale, though Cardinal's defensive beta profile differentiates its systematic risk characteristics.